about
Intact delay-eyeblink classical conditioning in amnesiaGuidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease researchToward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseRevolutionizing Alzheimer's disease and clinical trials through biomarkersA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkersAlzheimer's Disease prevalence, costs, and prevention for military personnel and veteransVascular contributions to cognitive impairment and dementia including Alzheimer's diseaseThe Worldwide Alzheimer's Disease Neuroimaging Initiative: An updateWorldwide Alzheimer's disease neuroimaging initiativeBuilding a roadmap for developing combination therapies for Alzheimer's diseaseThe diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseThe biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues.Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation.Research priorities to reduce the global burden of dementia by 2025.Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative.2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease.Revision of the criteria for Alzheimer’s disease: A symposium.Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trialsRandomized controlled trials in mild cognitive impairment: Sources of variability.Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.Developing novel blood-based biomarkers for Alzheimer's diseaseNational Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's diseaseStrategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.Commonalities and challenges in the development of clinical trial measures in neurology.Developmental and withdrawal effects of adolescent AAS exposure on the glutamatergic system in hamstersNeuropsychiatric symptoms in Alzheimer's diseaseAssessment of cognition in early dementia.Down syndrome and Alzheimer's disease: Common pathways, common goals.CAP--advancing the evaluation of preclinical Alzheimer disease treatments.Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.CSF biomarker variability in the Alzheimer's Association quality control program.The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkersAppropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's AssociationGenetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease.Methodological issues in primary prevention trials for neurodegenerative dementia.A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.Early risk assessment for Alzheimer's disease.
P50
Q22122446-536FB8C2-3478-452E-8C7B-BA79F0BDBCB4Q24289435-3372E989-4E0E-40DB-8BD4-DA599B40098BQ24595802-12AD5037-77CD-4B73-9998-FF963A9E6994Q26744882-31617678-A4E9-4838-A0C3-505F58C1B909Q26745508-5ACD42AF-8F55-4560-8F40-B36D3F3BAF5DQ26829862-737ADAF5-66CC-41C6-9FFE-C60CAABF8BE1Q26852882-BE73CE4F-58FC-4477-8555-4C8F21F41FD2Q27007843-0FBBC66C-6849-41DD-BF0B-431E55414A50Q27010338-4F754FB7-0B50-499E-BB8A-FA17D4E1F7DEQ28611100-8EA62796-E653-433C-A945-3EA695AC3124Q29614406-DB2EFABD-0F0B-4148-9A57-3E2FBB1BF69DQ30235204-396C9FA2-5416-4820-8008-4B4105DCE51FQ30239964-AE0D79E0-560F-4F25-BB89-6D0089D8BBFAQ30244419-0A170E8D-6060-4283-9CFD-8F2FAD9B2B1EQ30244954-865CDAB4-D3C2-4B33-80BA-CC4A02B36105Q30303063-01B2A807-0C9C-4DC7-9B2A-DF306F0DBD13Q30452902-0E03AA01-BBD7-4872-AC25-09B70BA8BD20Q30996727-F0E5AD18-0E40-48E7-9582-33C55FDF3F08Q31093236-464174C5-9756-4586-9F79-86F0E3B92A98Q33617293-B0B6521C-6B5D-445E-B13F-2C6BAA9E9BD7Q33969633-8ABAB03D-5AAA-4D7E-8E62-2FCB246C0620Q34394080-78ADC053-058C-47BF-8935-C66A346BA070Q34635272-979F03FE-58CB-44E0-AFBC-068D47DB772DQ34682521-C559BE0C-5C9B-4FDC-86BD-EA5D3CB04B1DQ34984743-78AFC391-938B-47E8-B9A6-B7544BBA22B0Q34988061-C6ACFC33-DD22-42C9-83C1-459ACB714D79Q35064956-25963DEB-E938-4004-AB0B-439A2B7D0867Q35090118-24BC206C-85D7-48E1-8BBB-85FDA8B3AF11Q35823575-EC62B0F8-A453-4270-91E4-E23311D7C882Q36733293-576BD2E2-61E9-4045-8C99-11180C102E9EQ36757252-E30DBA1C-CE2C-4541-A8BF-EAB9ABE02E87Q36843004-08E3663E-FD6A-4911-A373-7AA84E34CE20Q36885357-1AB36BF1-691D-44B5-B4BA-F9D9A8103EF5Q36999855-B8C7E2B3-16AC-496B-B88A-1AC29E13E596Q37008887-9EE68181-8D6D-4769-AB2E-DC6C245AD1A5Q37069527-DB7DC7B5-39FE-4A7A-96CF-21C3EBEB1060Q37170503-A8510CDC-D603-45B9-9419-DC50DB1CA732Q37394535-EC9C16C8-5E16-4A2F-9244-02A3DEACE7FFQ37425789-5C35B5F5-C716-422A-B4BB-2FD08AFCB84AQ37425804-72C09F5C-0C6D-4141-8935-30889297DB6B
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Maria C Carrillo
@ast
Maria C Carrillo
@en
Maria C Carrillo
@es
Maria C Carrillo
@nl
Maria C Carrillo
@sl
type
label
Maria C Carrillo
@ast
Maria C Carrillo
@en
Maria C Carrillo
@es
Maria C Carrillo
@nl
Maria C Carrillo
@sl
prefLabel
Maria C Carrillo
@ast
Maria C Carrillo
@en
Maria C Carrillo
@es
Maria C Carrillo
@nl
Maria C Carrillo
@sl
P214
P106
P21
P214
P31
P496
0000-0003-3057-2387
P734
P735
P7859
lccn-n2012180542